Kailera Therapeutics

Eli Lilly and Company

Shares of biotech Kailera Therapeutics Inc. are available for trading on the Freedom client trading platform. The company’s lead asset, ribupatide, is part of the multibillion-dollar race for weight-loss drugs, a market expected to exceed $150 billion over the next decade. Later on Friday, the stock will start regular-session trading on the Nasdaq under the ticker symbol <a href="https://tap.freedom24.com/to/quote/HMH.US?utm_source=stocks&amp;utm_medium=HMH.US&amp;utm_campaign=pfu17521958">KLRA</a>.

Kailera Therapeutics IPO: Shares of obesity drugmaker start trading

Bank of America reaffirmed its "buy" recommendation for shares of pharmaceutical company Eli Lilly and raised the target forecast for its securities from $950 to $1286, CNBC <a href="https://www.cnbc.com/2025/12/02/bank-of-america-hikes-eli-lilly-price-target-on-promising-drug-pipeline.html">reports</a>. This estimate assumes growth of about 22% from the current figures.

"Confident Leadership. Bank of America expects Eli Lilly shares to grow by more than 20%

Novo Nordisk A/S

By contrast, the shares of Eli Lilly's competitor, Ozempic manufacturer Novo Nordisk, fell 4%

Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose

China has entered the race in the market of weight loss drugs: several companies from China have presented their products that may become competitors to Ozempic, Mounjaro and other hits from Novo Nordisk and Eli Lilly. The first of these received regulatory approval in June. In general, Chinese biotech has survived the prolonged "nuclear winter" and is now actively developing. What should an investor know about it?